Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News from Liquidia

Insmed Catapults Into Breakout Territory On A 'Home Run' For Its Rival To United, Liquidia

Insmed stock catapulted into breakout territory early Tuesday after the biotech company hit a "home run" with its treatment for PAH.

Investors Business Daily

Stocks To Watch: Liquidia Sees Relative Strength Rating Jump To 93

Stocks To Watch: Liquidia Sees Relative Strength Rating Jump To 93

A Relative Strength Rating upgrade for Liquidia shows improving technical performance.

Investors Business Daily

Liquidia Clears Key Benchmark, Hitting 90-Plus RS Rating

Liquidia Clears Key Benchmark, Hitting 90-Plus RS Rating

A Relative Strength Rating upgrade for Liquidia shows improving technical performance.

Investors Business Daily

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Liquidia Scores Relative Strength Rating Upgrade

Liquidia shows rising price performance, earning an upgrade to its IBD Relative Strength Rating.

Investors Business Daily

Stocks To Watch: Liquidia Sees Relative Strength Rating Jump To 88

Liquidia shows rising price performance, earning an upgrade to its IBD Relative Strength Rating from 72 to 88.

Investors Business Daily

Liquidia Shows Rising Relative Price Performance; Still Shy Of Key Threshold

A Relative Strength Rating upgrade for Liquidia shows improving technical performance. Will it continue?

Investors Business Daily

Why Liquidia Stock Just Reversed Its Seven-Day Sprint And Crashed 31%

Liquidia stock crashed Monday after the FDA delayed the final approval for its drug, Yutrepia, for patients with a pair of lung diseases.

Investors Business Daily

inkl

Read news from The Economist, FT, and more,
with one subscription

Liquidia Stock Surges After Winning Patent Battle Vs. United Therapeutics

Liquidia Stock Surges After Winning Patent Battle Vs. United Therapeutics

Liquidia stock retook its 50-day line on a U.S. judge's ruling on a patent dispute with United Therapeutics.

Investors Business Daily

Benzinga's Top Ratings Upgrades, Downgrades For September 1, 2022

Benzinga's Top Ratings Upgrades, Downgrades For September 1, 2022

Liquidia: Q1 Earnings Insights

Liquidia: Q1 Earnings Insights

Liquidia (NASDAQ:LQDA) reported its Q1 earnings results on Thursday, May 12, 2022 at 06:30 AM. Here's what investors need to know about the announcement.

Liquidia Shares Slide On Proposed Public Offering

Liquidia Shares Slide On Proposed Public Offering

Liquidia Corp (NASDAQ: LQDA) has commenced an underwritten public offering of its common stock. All of the shares are to be sold by the company.

Liquidia: Q4 Earnings Insights

Liquidia: Q4 Earnings Insights

Liquidia (NASDAQ:LQDA) reported its Q4 earnings results on Thursday, March 17, 2022 at 06:30 AM. Here's what investors need to know about the announcement.

Organisations

Investor Business Daily

Western Digital

Bed, Bath & Beyond

Vulcan Materials

Paycom Software

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Topics

inkl

Read news from The Economist, FT, and more,
with one subscription

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.

Download on the AppStore

Get it on Google Play